comparemela.com

Latest Breaking News On - ஐ மருந்துகள் ஜமைக்கா - Page 2 : comparemela.com

Aion Therapeutic s Dr De La Haye to Speak at the CanEx Psychedelics Summit

Aion Therapeutic s Dr De La Haye to Speak at the CanEx Psychedelics Summit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLa hayeZuid hollandUniversity of the west indiesSaint andrewAnne donohoePhil carlsonGraham simmondsA johns hopkinsJohns hopkins universityAion therapeutic incFaculty of medical sciencesAssociation of jamaicaMinistry of healthAi pharmaceuticals jamaicaJamaica fulbright alumni association

Aion Therapeutic s Dr De La Haye to Speak at the CanEx Psychedelics Summit

Aion Therapeutic s Dr De La Haye to Speak at the CanEx Psychedelics Summit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesLa hayeZuid hollandUniversity of the west indiesSaint andrewAnne donohoePhil carlsonGraham simmondsA johns hopkinsJohns hopkins universityAion therapeutic incFaculty of medical sciencesAssociation of jamaicaMinistry of healthAi pharmaceuticals jamaicaJamaica fulbright alumni association

Investegate |Apollon Formularies Announcements | Apollon Formularies: Apollon Formulations Kill TNBC Cells

Apollon Formulations Kill Triple-Negative Breast Cancer (TNBC) Cells Apollon Formularies plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on Aquis Stock Exchange, is pleased to announce that its proprietary medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) cells in 3D cell cultures in third party independent laboratory testing. This finding is in addition to the results recently announced on May 18, 2021, that Apollon formulations were successful in killing HER2+ breast cancer cells. This testing was performed under a joint testing agreement with Aion Therapeutic Inc. (CSE: AION) ( Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange.

United kingdomUnited statesRichard pazdurHerberta fritscheMegan rayPaul burkeTim blytheStephend barnhillStene jacobsAion therapeutic incApollon formularies jamaicaDirectors of the companyOncology centerMd anderson cancer centerResearch developmentAi pharmaceuticals jamaica

Aion Therapeutic Announces Closing of Non-Brokered Private | The Kingston Whig Standard

Toronto, Ontario (Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ( Aion Therapeutic or the Company ) is pleased to

United statesAnne donohoePhil carlsonGraham simmondsAion therapeutic incStrategic communicationsNewsfile corpAi pharmaceuticals jamaicaCanadian securities exchangeCommon share of the companyAion therapeutic announces closingNon brokered private placementAion therapeuticCommon shareEach warrantExpiry date

Aion Therapeutic Announces Closing of Non-Brokered Private Placement

Toronto, Ontario (Newsfile Corp. - June 11, 2021) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce the closing of a non-brokered private placement through the issuance of 16,994,475 units (each, a "Unit") at a price of $0.0875 per Unit for gross proceeds of $1,487,016.56 (the "Offering"). The proceeds of the Offering will be used by the Company for general working capital purposes.Each Unit is comprised of one .

United statesAnne donohoeGraham simmondsPhil carlsonAion therapeutic incStrategic communicationsAi pharmaceuticals jamaicaNewsfile corpCanadian securities exchangeCommon share of the companyCommon shareEach warrantExpiry dateCommon sharesCanadian securitiesEach broker warrant

vimarsana © 2020. All Rights Reserved.